[Results] 88 weeks on 2.4mg, full numbers, ask me anything boring
Six-word version is the title — 88 weeks on 2.4mg, full numbers, ask me anything boring — and the rest is context.
Hard numbers: 88 weeks and 2.4mg. Anything softer than that is flagged as an impression.
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.
[removed by moderator]
Not convinced. You are attributing a week of injection-site soreness to the glucagon arm when the escalation rate alone would explain it.
wait for phase 3 before you argue about rankings
Has anyone posted an independent test on this compound recently?
Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running. Everything else is inference.
the energy-expenditure story is mechanistically interesting and clinically unproven
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.
the escalation is where most of the reported trouble sits
Are you comparing against phase 3 numbers for something else? They are not comparable.
Is that the 48-week figure or an earlier readout?
Is that the 48-week figure or an earlier readout?
Agreed, and the glucagon arm is exactly why the comparison threads do not work.
What the glucagon arm is doing, as best anyone can say from public data.
GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.
Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.
What the glucagon arm is doing, as best anyone can say from public data.
Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.
How fast was the escalation? That is usually the variable that explains the reports.
What the glucagon arm is doing, as best anyone can say from public data.
This is the sentence the rest of the board should read first. Phase 2 is not a label.
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.
This is the sentence the rest of the board should read first.
devils_advocate_d is right about the escalation being the variable. It explains most of the difficult reports here.
dose escalation in the trials was slow for a reason
phase 2 data only, and people quote it like it is a label
What the glucagon arm is doing, as best anyone can say from public data.
Adding the standing caveat: none of this is approved anywhere and research material is not for human use.
- 1What the glucagon arm is doing, as best anyone can say from public data.…9 comments in this branch · started by u/blunt_coldbox_2024
- 2Phase 2 estimates effect and finds a dose range. Phase 3 estimates it…7 comments in this branch · started by u/nadia_trevino